在接受含有复杂蛋白质的肉毒素配方治疗的患者中,对抗复杂蛋白抗体的交叉诱导
Yuttana Srinoulprasert1, Surachet Sirisuthivoranunt2, Chattip Sripatumtong1
1Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Toxins
|February 26, 2026
概括
含有复合蛋白质 (CP) 的不同类型A型肉毒素 (BoNT/A) 产品可以触发交叉反应性抗体. 无CP的incobotulinumtoxinA显示出最小的免疫性,这表明CP含量会影响抗体反应.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 毒素A型 (BoNT/A) 配方在无毒的辅助复合蛋白 (CP) 中有所不同.
- 抗菌素可能会影响BoNT/A产品的免疫性.
- 不同的BoNT/A产品中CP的结构相似性可能导致抗体交叉反应.
研究的目的:
- 研究不同BoNT/A配方治疗的患者中交叉反应性抗CP抗体的发展.
- 根据其CP含量,比较各种BoNT/A产品的免疫性.
主要方法:
- 在五个治疗组 (incobotulinumtoxinA,onabotulinumtoxinA,abobotulinumtoxinA,letibotulinumtoxinA,prabotulinumtoxinA) 中进行了100名参与者的前性研究.
- 标准化剂量 (50 个单位或同等剂量) 被使用.
- 在注射后180天收集的血清样本使用吸收ELISA对抗CP抗体进行了分析,与先前没有毒素的对照组相比.
主要成果:
- 毒素A没有诱导显著的抗CP抗体反应.
- 毒素A,毒素A和毒素A组对多个CP的抗体水平较高,表明交叉反应性.
- 阿博托毒素A主要诱导抗体对自己的CP和prabotulinumtoxinA的抗体.
结论:
- 含有CP的BoNT/A配方可以诱导交叉反应性抗体反应.
- 没有CP的incobotulinumtoxinA表现出极小的免疫性.
- 在选择BoNT/A产品时,CP成分至关重要,特别是对于需要重复治疗的患者.
更多相关视频
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.3K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.3K
Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.1K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.1K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.2K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.2K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.7K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.7K
Antibody Actions
3.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.1K


